Filer Snapshot

Citius Pharmaceuticals, Inc.

CIK 0001506251. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

53

Latest filing

04 Jun 2026

Industry

Pharmaceutical Preparations

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13D/G stake for CTOR. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open 13D/G history Save page

Largest parsed holding

—

Populates from the latest parsed 13F information table.

Open holding

13D/G large stake

CTOR

15 May 2026 · 71% ownership

Open 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC Schedule 13D/G

SCHEDULE 13D/A filed on 04 Jun 2026 for CIK 0001506251.

View source filing
Listed symbols
CTXR on Nasdaq
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Largest active 13D stakes

Active large-stake positions disclosed in parsed Schedule 13D filings.

CTOR
How to read these SEC ownership signals
  • Read each filing family separately: Form 13F, Schedules 13D/G, and Forms 3/4/5 answer different SEC disclosure questions and should not be blended into one ownership total.
  • Use 13F values for visible U.S.-listed equity portfolios, 13D/G rows for large beneficial-owner stakes, and Forms 3/4/5 rows for reporting-owner positions and transactions.
  • Open the linked research path when you need the filing, CIK, issuer, CUSIP, date, or source trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 2 identity fields
SEC industry group
Pharmaceutical Preparations (Office of Life Sciences)
Business address
11 Commerce Drive, 1 St Floor, Cranford, NJ, 07016
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 3 profile fields available
Incorporated in
NV
Fiscal year end
30 September
Former names on EDGAR
Trail One, Inc. (to 18 Sep 2014), TrailOne, Inc. (to 21 Jan 2011)

Filer intelligence

What SEC filings say about Citius Pharmaceuticals, Inc.

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Save filer

Quick read

  • 1 recent 13D/G stake row found; top row is CTOR at 71% ownership.
  • Forms 3/4/5 show insider context for CTOR.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio No rows yet

Quarterly institutional portfolio holdings.

Open
13D/G stakes 1 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 1 rows

Officer, director, and 10% owner holdings or transactions.

Open

13D/G large-stake context

CTOR

15 May 2026 · Common Shares, $0.0001 par value per share

71%
Issuer page 13D/G history

Forms 3/4/5 insider context

CTOR

12 Aug 2024 · 10% owner

Issuer page Owner page

Latest update

What changed recently for Citius Pharmaceuticals, Inc.

New filing available

Latest Schedule 13D/G period: 15 May 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

04 Jun 2026

Page type

Filer profile

Latest period

15 May 2026

Schedule 13D/G context is visible from filings filed on 04 Jun 2026.

Open filer profile Browse recent public updates

Benchmark Context

Benchmark context for this company

Citius Pharmaceuticals, Inc. has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest Schedule 13D/G period: 15 May 2026. That gives you a fresh baseline before you compare this company with peers.

  • Latest company facts filing date: 15 May 2026.
  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0001506251 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
53
First seen
26 Jul 2021
Latest filing
04 Jun 2026
Entity
Company

Observed form types

10-K 10-K/A 10-Q 3 4 SCHEDULE 13D/A

CIK-linked evidence first

Citius Pharmaceuticals, Inc. SEC filings Citius Pharmaceuticals, Inc. 13D/G history Citius Pharmaceuticals, Inc. owner filings Citius Pharmaceuticals, Inc. insider transactions Citius Pharmaceuticals, Inc. company facts Open SEC filing index

Industry context: Pharmaceutical Preparations.

Latest Filings

Showing the latest 12 of 53 SEC filings for Citius Pharmaceuticals, Inc..

Open full filing history
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
04 Jun 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q

10-Q filing

Filing date
15 May 2026
Reporting date
31 Mar 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q

10-Q filing

Filing date
13 Feb 2026
Reporting date
31 Dec 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
10-K

10-K filing

Filing date
23 Dec 2025
Reporting date
30 Sep 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
17 Dec 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
23 Sep 2025
Reporting date
08 Aug 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
12 Sep 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

4 filing

Filing date
12 Aug 2025
Reporting date
08 Aug 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q

10-Q filing

Filing date
12 Aug 2025
Reporting date
30 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
25 Jul 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q

10-Q filing

Filing date
14 May 2025
Reporting date
31 Mar 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q

10-Q filing

Filing date
14 Feb 2025
Reporting date
31 Dec 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .